REAL-WORLD EXPERIENCE WITH FOSTAMATINIB FOR TREATMENT OF IMMUNE THROMBOCYTOPENIA (ITP): PATIENT-REPORTED OUTCOMES
a Divisions of Hematology/Oncology and Pediatric Hematology-Oncology, Weill Cornell Medical College, New York, United States
b Departments of Medical Affairs and Market Access, Rigel Pharmaceuticals, Inc., South San Francisco, CA, USA
c Claritas Rx, Inc, South San Francisco, United States
d Knight Therapeutics, São Paulo, Brazil
Lido
991
Vezesque se leu este artigo
392
Total PDF
599
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 7 | 59 | 25 | 84 |
| 2025 6 | 37 | 16 | 53 |
| 2025 5 | 47 | 10 | 57 |
| 2025 4 | 40 | 13 | 53 |
| 2025 3 | 56 | 8 | 64 |
| 2025 2 | 43 | 19 | 62 |
| 2025 1 | 25 | 27 | 52 |
| 2024 12 | 22 | 9 | 31 |
| 2024 11 | 31 | 15 | 46 |
| 2024 10 | 29 | 17 | 46 |
| 2024 9 | 30 | 23 | 53 |
| 2024 8 | 26 | 26 | 52 |
| 2024 7 | 27 | 21 | 48 |
| 2024 6 | 25 | 18 | 43 |
| 2024 5 | 21 | 27 | 48 |
| 2024 4 | 21 | 16 | 37 |
| 2024 3 | 17 | 19 | 36 |
| 2024 2 | 11 | 20 | 31 |
| 2024 1 | 7 | 7 | 14 |
| 2023 12 | 10 | 24 | 34 |
| 2023 11 | 12 | 26 | 38 |
| 2023 10 | 3 | 6 | 9 |
Mostrar tudo
